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DIAGNOSING GVHD WITH A SIMPLE BLOOD TEST? CD4+ AND CD8+ T
CELL GRANYZME B EXPRESSION MAY HOLD THE KEY
Srinivasan, S.2, Hill, K.1, Blazar, B.3, Kean, L.1 1Emory University;
2Emory University; 3University of Minnesota
The diagnosis of GvHD currently relies on clinical criteria cou-
pled with histopathologic analysis of biopsy samples. However, the
sickest patients are often too ill to permitGI or liver biopsy, resulting
in significant diagnostic uncertainty for the patients who are at most
risk for GvHD morbidity and mortality. Thus, there is a pressing
need to develop a sensitive and specific test for GvHD that is amena-
ble to routine monitoring in the peripheral blood.
Using the Primate GvHDModel we have determined that Gran-
zyme B expression is massively upregulated in T cells causing
GvHD.We analyzed the T cell phenotype in a cohort of Rhesus ma-
caques who had received MHC-mismatched HSCT in the absence
of immunosuppression, and who had histopathologically-proven
GvHD. One of the most striking phenotypic changes that correlated
with GvHD was the massive upregulation of Granzyme B on both
CD4+ and CD8+ T cells: The per-cell Mean Fluorescence Intensity
(MFI) forGranzymeB duringGvHD increased by asmuch as 10-25-
fold for both CD4+ and CD8+ T cells compared to pre-transplant
expression levels.
Importantly, Granzyme B upregulation was independent of T cell
proliferation: Animals that had undergone autologous transplant and
who were undergoing T cell reconstitution by homeostatic prolifer-
ation did not upregulate Granzyme B on either CD4+ or CD8+ T
cells. Thus, while the average Granzyme B MFI was 1.97x105 and
1.15x105 for CD8+ and CD4+ T cells causing GvHD, the MFI in
CD4+ and CD8+ T cells expanding after autologous transplant
was 9.6-fold and 11.7-fold lower, despite ongoing T cell prolifera-
tion in these animals (p\0.0001). Immunosuppressed animals reac-
tivating CMV also did not upregulate Granzyme B on either CD4+
or CD8+ T cells (Granzyme B MFI0.24x105 and 0.074x105, respec-
tively, corresponding to a 8.2-fold and 15.5-fold reduction compared
to T cells causing GvHD, p\ 0.0001).
Our results suggest that Granzyme B expression may be a highly
discriminating phenotypic marker of GvHD, able to distinguish T
cells causing GvHD from those undergoing homeostatic expansion
or those activated during CMV viremia. This observation could be
translated into a flow-cytometric test for GvHD in the peripheral
blood, which could significantly improve our ability to accurately di-
agnose this devastating disorder. These observations also implicate
Granzyme B in the pathogenesis of GvHD, and identify this enzyme
as a potential target for GvHD prevention and treatment.484
GENETICALLY ENGINEERED DONOR T CELLS FOR BMT IMMUNOTHER-
APY: EXPRESSION OF TRAIL AND PLZF SELECTIVELY ENHANCES GVT
AND ABROGATES GVHD
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We assessed two novel strategies in whichT cells (mature and pre-
cursors) were genetically engineered to enhance select effector func-
tions and improve graft versus tumor (GVT) effects without
exacerbating graft versus host disease (GVHD).
One strategy relies on T cell cytolytic molecule TNF-Related Ap-
optosis Inducing Ligand (TRAIL), which induces apoptosis through
death receptors (DR) 4 and 5 (onlyDR5 inmice). Certain tumor cells
express high levels ofDR5makingTRAIL an attractive candidate for
engineering T cells to augment GVT. Mature T cells were trans-
duced with a lentiviral TRAIL expression vector and adoptively
transferred into lethally irradiated allogeneic bone marrow trans-
plantation (allo-BMT) recipients, bearing LB27.4 tumors (B6 /
CBF1+LB27.4). TRAIL+ T cells had enhanced antitumor effect
compared to control-transduced T cells in vitro and upon transfer
into tumor-bearing allo-BMT recipients (p\ 0.01). Interestingly,the recipients of TRAIL+ T cells had significantly less GVHD. We
generated TRAIL+ precursor (pre)T cells using the OP9-DL1 co-
culture system. Adoptive transfer of B6 TRAIL+ preT cells into syn-
geneic-transplanted BALB/c mice resulted in reconstitution with
TRAIL+ T cells. When challenged with localized RENCA tumors,
recipients of TRAIL+ preT cells had enhanced antitumor activity
(p\0.05) compared to recipients of control-transduced preT cells.
The second strategy explores the effect of overexpressing the
transcription factor promyelocytic leukemia zinc finger (PLZF) in
T cells. PLZF transgenic (tg) T cells have an effector/memory phe-
notype with innate-like characteristics. Following transfer, they cells
display an altered cytokine profile with increased expression of
TNFa and decreased IFNg. Using adoptive transfer of CFSE-la-
beled donor T cells we observed that fast proliferating allo-respon-
sive PLZF+ T cells died after only a few cell cycles. Using PLZF
tg mice, we found that PLZF+ T cells cause less GVHD with intact
GVT activity (p\ 0.001) against A20 lymphoma. We then trans-
duced T cells with PLZF expression vector and confirmed that
donor PLZF+ T cells have less GVHD and intact GVT activity.
Our data suggest that adoptive therapy with genetically engi-
neered TRAIL+ or PLZF+ T cells cause less GVHD while display-
ing intact or enhanced GVT activity. Furthermore, the ‘‘off the
shelf’’ use of genetically enhanced preT cells represents a promising
cell therapy strategy to enhance anti-tumor activity in both autolo-
gous and allo-BMT patients.485
CHANGES IN CD4+ T CELLS AND REGULATORY T CELLS (TREG) IN
CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Grogan, B.M.1, Tabellini, L.1, Storer, B.1,2, Bumgarner, T.E.1,
Haeusermann, P.1, Astigarraga, C.C.1, Flowers, M.E.D.1,2, Lee, S.J.1,2,
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The role that CD4+T cells, specifically CD4+FOXP3+Tregs, play
in cGVHD following hematopoietic cell transplantation (HCT) is
unclear. We performed a cross-sectional analysis of 218 HCT pa-
tients studied between9 to 271months post-HCT to test the hypoth-
esis that increased activation and proliferation of CD4+ T cells
distinguishes patients with cGVHD from patients who have devel-
oped clinical tolerance (defined as no active chronic GVHD for 6
months without immunosuppression therapy {IST}), and to deter-
mine if changes in Treg are associated with cGVHD. Four groups
were studied: patients with cGVHD on IST (n 5 100), patients
with cGVHD without IST (n 5 66), tolerant patients (n 5 52) and
normal controls (n5 50).We observed no statistically significant dif-
ference in #Treg, %Treg/PBL or Foxp3 gene expression compared
to cGVHD patients without IST, tolerant patients, and normal
controls. Significant decreases in the # and %Treg, and Foxp3 gene
expression, however, were present in patients with cGVHD on IST
(p 5 0.004, p\ 0.001, and p\ 0.001, respectively). We found de-
creased CD62L and increased CD95 expression on Treg in cGVHD
patients without IST compared to normal controls (53.662.9% vs.
65.162.1%, p 5 0.001, and 77.762.3% vs. 62.362.6, p\ 0.001)
which normalized in tolerant patients (65.461.8% p 5 ns, and
69.462.6%, p5 ns).We observed increased activation, proliferation
and apoptosis in the overall CD4+ T cell population in cGVHD pa-
tients, especially without IST, with an increased expression of HLA-
DR (5.860.6% vs. 3.560.3%, p\ 0.001), CD95 (59.162.8% vs.
45.062.0%, p\ 0.001) and Ki-67 (6.261.0% vs. 3.360.3%, p 5
0.008) compared to normal controls. HLA-DR andKi-67 expression
normalized in tolerant patients (3.460.3%, p 5 ns; 3.960.5%, p 5
ns). The increased expression of activation markers in patients with
cGVHD was accompanied by a decrease in the expression of CCR7
and CD62L, which normalized in tolerant patients. Proliferation
and expression of activation markers were significantly decreased in
cGVHD patients with IST compared to without IST. In summary,
cGVHD is characterized by increased activation and proliferation
ofCD4+T cells compared to those from tolerant patients and healthy
controls. The # and%Treg and Foxp3 expression were lower during
IST but were not otherwise correlated with cGVHD. Treg in
cGVHD show increased apoptosis and loss of receptors required
for migration to peripheral tissues and lymph nodes, which may
reduce Treg interactions with T effector cells.
